Intracerebral hemorrhage

Portola Pharmaceuticals to Support New American Heart Association Initiative to Address Hemorrhagic Stroke

Retrieved on: 
星期二, 十二月 17, 2019
Stroke, RTT, Cerebrovascular diseases, Neurotrauma, Intracerebral hemorrhage, Medical specialties, Bleeding, Medicine, Epidemiology, Cerebrovascular disease, Silent stroke

SOUTH SAN FRANCISCO, Calif., Dec. 17, 2019 /PRNewswire/ --Portola Pharmaceuticals, Inc. (Nasdaq: PTLA) today announced its support of the American Heart Association/American Stroke Association's newest initiative for enhanced awareness and understanding of best care practices for hemorrhagic stroke, or severe bleeding in the brain.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Dec. 17, 2019 /PRNewswire/ --Portola Pharmaceuticals, Inc. (Nasdaq: PTLA) today announced its support of the American Heart Association/American Stroke Association's newest initiative for enhanced awareness and understanding of best care practices for hemorrhagic stroke, or severe bleeding in the brain.
  • Intracerebral hemorrhage (ICH), or hemorrhagic strokes, make up about 10 percent of the 795,000 stroke cases per year.
  • A hemorrhagic stroke occurs when a weakened blood vessel ruptures and spills blood into the brain.
  • More information about this initiative will be announced at the American Heart Association/American Stroke Association's annual International Stroke Conference, February 18-21, 2020.

Third FDA Clearance for Zebra-Med's AI Solution for Brain Bleeds Alerts

Retrieved on: 
星期一, 六月 17, 2019
Neurotrauma, Stroke, Medical specialties, Medicine, Cerebrovascular diseases, RTT, Intensive care medicine, Health, Intracranial hemorrhage, Intracerebral hemorrhage, Triage

The latest cleared product automatically identifies suspected internal brain bleeds based on non-contrast head CTs for triaging, significantly reduces turnaround time, and increases the radiologists' confidence in their diagnosis.

Key Points: 
  • The latest cleared product automatically identifies suspected internal brain bleeds based on non-contrast head CTs for triaging, significantly reduces turnaround time, and increases the radiologists' confidence in their diagnosis.
  • Zebra-Med's intracranial hemorrhage triage solution can provide early detection of people who may have experienced a brain bleed.
  • The growing number of FDA approvals within Zebra-Med's AI portfolio allows the company to expand its presence in the US market.
  • Zebra Medical Vision has raised $50 million in funding to date, and was named a Fast Company Top-5 AI and Machine Learning company.

MaxQ AI's Accipio™ Software Integrated as Part of GE Healthcare's Smart Subscription Platform Offering in the U.S. and E.U. Acute Care Markets

Retrieved on: 
星期二, 十一月 27, 2018
Neurotrauma, Medicine, Stroke, Medical tests, GE Healthcare, Magnetic resonance imaging, Radiopharmaceuticals, General Electric, Intracranial hemorrhage, Intracerebral hemorrhage, CT scan, Head injury

GE Healthcare'sSmart Subscriptionprovides customers with continuous access to the latest imaging software updates, through an available automatic download to their CT scanners from the cloud.

Key Points: 
  • GE Healthcare'sSmart Subscriptionprovides customers with continuous access to the latest imaging software updates, through an available automatic download to their CT scanners from the cloud.
  • As a Smart Subscription offering, hospitals with GE Healthcare CTs can easily and seamlessly integrate MaxQ's Accipio platform, of which Accipio Ix intracranial hemorrhage (ICH) detection software is now available, to support an acute care physician's ability to identify and prioritize brain bleed stroke or head trauma.
  • "Building on our successful collaboration with world-class GE Healthcare, we are pleased that our Accipio intracranial hemorrhage (ICH) detection software has been fully integrated as a function of the Smart Subscription platform," said Gene Saragnese, Chairman and CEO of MaxQ AI.
  • With Smart Subscription, customers can be confident that their GE Healthcare CT scanners will be up to date with the latest imaging software for the life of the system.

MaxQ AI Receives FDA Clearance for Accipio Ix™ Intracranial Hemorrhage Diagnostics Intelligence Platform

Retrieved on: 
星期三, 十一月 7, 2018
Neurotrauma, Stroke, Medicine, Health, Technology, Artificial intelligence, Cybernetics, Intracranial hemorrhage, Food and Drug Administration, Intracerebral hemorrhage, Bleeding

TEL AVIV, Israel and ANDOVER, Mass., Nov. 7, 2018 /PRNewswire/ --MaxQ AI, a clinical diagnostics intelligence platform company, today announced that its revolutionary Accipio Ix intracranial hemorrhage (ICH) detection software has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

Key Points: 
  • TEL AVIV, Israel and ANDOVER, Mass., Nov. 7, 2018 /PRNewswire/ --MaxQ AI, a clinical diagnostics intelligence platform company, today announced that its revolutionary Accipio Ix intracranial hemorrhage (ICH) detection software has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
  • "We are very pleased to receive FDA 510(k) clearance for Accipio Ix, which we believe will be a transformative solution for medicine," said Gene Saragnese, Chairman and CEO of MaxQ AI.
  • "MaxQ's Accipio application, of which Accipio Ix is the first part of the ecosystem, provides physicians with actionable intelligence, improving their future ability to make a timely, accurate and more confident diagnosis of a brain bleed."
  • MaxQ AI is at the forefront of transforming healthcare by empowering physicians to provide 'smarter care' with artificial intelligence (AI) clinical insights.

MaxQ-AI Receives CE Mark Approval for Accipio™Ix Intracranial Hemorrhage Artificial Intelligence Software Platform

Retrieved on: 
星期二, 五月 22, 2018
Neurotrauma, Stroke, Computational neuroscience, Intracranial hemorrhage, Artificial intelligence, Ai, Intracerebral hemorrhage, Technology, Culture, Nervous system

TEL AVIV, Israel, May 22, 2018 /PRNewswire/ -- MaxQ Artificial Intelligence (MaxQ-AI), a global artificial intelligence (AI) healthcare company, today announced that it has received the CE Mark approval for its revolutionary Accipio software platform.

Key Points: 
  • TEL AVIV, Israel, May 22, 2018 /PRNewswire/ -- MaxQ Artificial Intelligence (MaxQ-AI), a global artificial intelligence (AI) healthcare company, today announced that it has received the CE Mark approval for its revolutionary Accipio software platform.
  • MaxQ-AI has developed a broad machine vision and deep learning platform to support the assessment of multiple clinical indications.
  • The first of these applications will be the detection of intracranial hemorrhage (ICH), commonly known as a brain bleed.
  • "We are delighted to receive the CE Mark for AccipioIx, the first of many global regulatory approvals."

NICO Continues to Innovate with Smallest Trans-Sulcal Brain Access Tool in the World

Retrieved on: 
星期二, 五月 1, 2018
Medicine, Surgery, Clinical medicine, RTT, Neurotrauma, Biopsy, Stroke, Cerebrovascular diseases, Brain biopsy, Neurosurgery, Intracerebral hemorrhage, Human brain

The new device is part of the company's expanding neurosurgery product line that addresses primary and secondary brain tumors and intracerebral hemorrhages.

Key Points: 
  • The new device is part of the company's expanding neurosurgery product line that addresses primary and secondary brain tumors and intracerebral hemorrhages.
  • "The smaller caliber allows me to cannulate to the abnormality more efficiently and with less brain distortion, which is better for the patient."
  • Like the 13.5 mm diameter BrainPath, the 11 mm is a designed for non-disruptive access to brain abnormalities and brain biopsy.
  • The smaller 11 mm diameter affords the option for an even smaller footprint and less displacement of brain tissue.